Real-World data on tezepelumab for severe asthma: what happens outside trials?
NCT ID NCT06455462
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked back at medical records of 352 adults with severe asthma who started taking tezepelumab in UK hospitals between January 2023 and March 2024. Researchers wanted to see how often patients had asthma attacks and whether they needed oral steroids during the year after starting the drug. Because it's an observational study, it doesn't test the drug but describes what happens in real-world care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tezepelumab
What this could lead to
If the results show tezepelumab works well in real-world settings, it could support its use as a standard treatment for severe asthma.
What could go wrong
This is a retrospective chart review, not a controlled trial, so it can't prove cause and effect. Results may be influenced by how doctors chose patients for treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Birmingham, United Kingdom
-
Research Site
Liverpool, United Kingdom
-
Research Site
London, United Kingdom
-
Research Site
Newcastle, United Kingdom
-
Research Site
Plymouth, United Kingdom
-
Research Site
Southampton, United Kingdom